What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
Answer from: Medical Oncologist at Community Practice
More information will be helpful in approaching this case.
Was this a de novo presentation or a recurrence case?
Was the ERBB2 IHC done on the primary tumor or a metastatic lesion?
Was the ERBB2 amplification detected in tissue (primary or metastatic)? At what point in time was this...
Comments
Medical Oncologist at University of Utah
Recurrence in AI
Hepatic metastasis
Meta...
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center Thank you @Austin for providing more informat...
Medical Oncologist at University of Utah Thank you!
Medical Oncologist at University of Utah Sorry to bother you again. Would you favor a TKI o...
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center Not necessarily. I would consider Trastuzumab/Pert...
Medical Oncologist at NYU Winthrop Hospital T-DXd is approved in 2nd line therapy: DESTINY-Bre...
Recurrence in AI Hepatic metastasis Meta...
Thank you @Austin for providing more informat...
Thank you!
Sorry to bother you again. Would you favor a TKI o...
Not necessarily. I would consider Trastuzumab/Pert...
T-DXd is approved in 2nd line therapy: DESTINY-Bre...